Metastatic Prostate Cancer.

Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with metastatic prostate cancer have recently been noted to increase survival. Decisions about which treatments to use and in what order to maximize the benefit should be made on the basis of high-quality clinical trials.

[1]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[2]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[3]  D. Steinemann,et al.  Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores , 2017, Journal of Clinical Oncology.

[4]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[5]  F. Saad,et al.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.

[6]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[7]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, The Journal of Nuclear Medicine.

[8]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[9]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[10]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[11]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[12]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[13]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[14]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[15]  A. Armstrong,et al.  Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Larson,et al.  Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[17]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[18]  L. Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[19]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[20]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[21]  M. Dowsett,et al.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[23]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.